B+
Bull case
25%
Probability
Target price
$30.00
Analysis reference price unavailable
Analysis 2026-09-16 · RankAlpha Sentiment Codex
COLL
Collegium PharmaceuticalBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
50%
Probability
Target price
$23.25
Analysis reference price unavailable
Analysis 2026-09-16 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$16.50
Analysis reference price unavailable
Analysis 2026-09-16 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-09-16
Recent news sentiment (30D)
-0.2
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+55.1
Score
AI commentary
Recent coverage remains concentrated on Q2 results. Stored secondary context described a negative market reaction despite an adjusted-EPS beat and increased revenue guidance, while the September 15 anchor of $21.84 is below the cited post-earnings level. No sufficient social coverage, options skew, short-interest data, employee score or verified post-print analyst revisions were supplied; unavailable sentiment fields are represented as neutral placeholders and should not be interpreted as measured observations. The evidence supports cautious positive monitoring rather than a high-conviction rerating thesis.
RankAlpha Sentiment Codex - 2026-09-16
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-11-15catalystQ3 ADHD portfolio executionHigh impact
The next operating test is whether back-to-school demand sustains JORNAY PM growth and accelerates AZSTARYS after salesforce integration. Q2 JORNAY PM revenue increased 41% year over year, prescribers increased 17.6%, and AZSTARYS contributed $12.9 million for a partial quarter. [#SEC-8K-2026-08-06]
2026-12-31eventAccelerated share-repurchase settlementMedium impact
Final settlement of the accelerated share-repurchase agreement is expected no later than the fourth quarter of 2026, creating a defined capital-allocation checkpoint but not an operating catalyst. [#8-K-2026-08-13]
2027-08-31catalystADHD-led portfolio diversificationHigh impact
Sustained JORNAY PM growth and successful AZSTARYS commercialization could reduce reliance on the pain portfolio. The Q2 release reported record JORNAY PM adoption, completed AZSTARYS integration and an expanded commercial platform, while also acknowledging increased NUCYNTA pressure. [#SEC-8K-2026-08-06]
Recommendation
N/A
No formal recommendation provided.
As of 2026-09-16 • Updated nightlySource: Internal modelMethodology